Psoriatic arthropathy in patients with previous neoplasia: a case series of four patients treated with secukinumab and literature review
CONCLUSIONS: In conclusion, our case series, consisting of four PsA patients with concurrent neoplasia treated with secukinumab, showed no evidence of cancer progression and represents the first case of PsA described in the literature treated during active oncological disease, lending support to the safety of secukinumab for the treatment of patients with PsA and concomitant neoplasia.PMID:38639525 | DOI:10.26355/eurrev_202404_35919 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 19, 2024 Category: Drugs & Pharmacology Authors: U G Massafra F Giovannangeli A Migliore Source Type: research
Psoriatic arthropathy in patients with previous neoplasia: a case series of four patients treated with secukinumab and literature review
CONCLUSIONS: In conclusion, our case series, consisting of four PsA patients with concurrent neoplasia treated with secukinumab, showed no evidence of cancer progression and represents the first case of PsA described in the literature treated during active oncological disease, lending support to the safety of secukinumab for the treatment of patients with PsA and concomitant neoplasia.PMID:38639525 | DOI:10.26355/eurrev_202404_35919 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - April 19, 2024 Category: Drugs & Pharmacology Authors: U G Massafra F Giovannangeli A Migliore Source Type: research
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
J Dermatolog Treat. 2024 Dec;35(1):2340107. doi: 10.1080/09546634.2024.2340107. Epub 2024 Apr 18.ABSTRACTBrodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profile...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Lisa Schaeffer Nesrine Ben-Anaya Christina Sorbe Stephan Jeff Rustenbach Ulrich Mrowietz Matthias Augustin Source Type: research
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18.ABSTRACTIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52 by baseline demographics and clinical characteristics: ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index, minimal disease act...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Joseph F Merola April Armstrong Saakshi Khattri So Yeon Paek Byron Padilla Cuiyong Yue Huzefa Photowala Blair Kaplan Lars Erik Kristensen Source Type: research
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
J Dermatolog Treat. 2024 Dec;35(1):2340107. doi: 10.1080/09546634.2024.2340107. Epub 2024 Apr 18.ABSTRACTBrodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profile...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Lisa Schaeffer Nesrine Ben-Anaya Christina Sorbe Stephan Jeff Rustenbach Ulrich Mrowietz Matthias Augustin Source Type: research
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18.ABSTRACTIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52 by baseline demographics and clinical characteristics: ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index, minimal disease act...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Joseph F Merola April Armstrong Saakshi Khattri So Yeon Paek Byron Padilla Cuiyong Yue Huzefa Photowala Blair Kaplan Lars Erik Kristensen Source Type: research
Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period
CONCLUSIONS: Risk chart algorithms are very useful for discriminating PsA at low and high CV risk. An integrated model featuring QRISK3 and SCORE2 yielded the optimal synergy of QRISK3's discrimination ability and SCORE2's calibration accuracy.PMID:38631846 | DOI:10.1136/rmdopen-2024-004207 (Source: Atherosclerosis)
Source: Atherosclerosis - April 17, 2024 Category: Cardiology Authors: Jessica Polo Y La Borda Santos Casta ñeda Elena Heras-Recuero Fernando S ánchez-Alonso Zulema Plaza Carmen Garc ía Gómez Ivan Ferraz-Amaro Jes ús Tomás Sanchez-Costa Olga Carmen S ánchez-González Ana Isabel Turri ón-Nieves Ana Perez-Alcal á Caro Source Type: research
Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period
CONCLUSIONS: Risk chart algorithms are very useful for discriminating PsA at low and high CV risk. An integrated model featuring QRISK3 and SCORE2 yielded the optimal synergy of QRISK3's discrimination ability and SCORE2's calibration accuracy.PMID:38631846 | DOI:10.1136/rmdopen-2024-004207 (Source: Atherosclerosis)
Source: Atherosclerosis - April 17, 2024 Category: Cardiology Authors: Jessica Polo Y La Borda Santos Casta ñeda Elena Heras-Recuero Fernando S ánchez-Alonso Zulema Plaza Carmen Garc ía Gómez Ivan Ferraz-Amaro Jes ús Tomás Sanchez-Costa Olga Carmen S ánchez-González Ana Isabel Turri ón-Nieves Ana Perez-Alcal á Caro Source Type: research
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
ConclusionsThis meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies. (Source: Drugs)
Source: Drugs - April 17, 2024 Category: Drugs & Pharmacology Source Type: research
